尼古丁吸入剂用于孕妇戒烟随机试验
本研究为随机双盲安慰剂对照试验,纳入每日吸烟≥5支的孕妇,接受行为咨询并随机分配至尼古丁吸入剂组(n=70)或安慰剂组(n=67),治疗6周后逐渐减量6周。主要结局为妊娠32-34周戒烟率,两组相似(10% vs 18%,p=0.220)。尼古丁组早产发生率低于安慰剂组(4% vs 15%,p=0.030),低出生体重发生率亦较低(6% vs 15%,p=0.035),但校正早产后无统计学差异(p=0.268)。
要点
- 尼古丁吸入剂组与安慰剂组在妊娠32-34周戒烟率无显著差异(10% vs 18%,p=0.220)。
- 尼古丁吸入剂组早产发生率低于安慰剂组(4% vs 15%,p=0.030)。
- 低出生体重发生率尼古丁组低于安慰剂组(6% vs 15%,p=0.035),校正早产后无显著差异(p=0.268)。
核心结论
- 尼古丁吸入剂组妊娠期戒烟率未高于安慰剂组,但早产发生率低于安慰剂组。
研究设计与样本
- 随机双盲安慰剂对照试验,纳入每日吸烟≥5支的孕妇,接受行为咨询并随机分配至6周尼古丁吸入剂或安慰剂治疗,随后6周逐渐减量。
- 尼古丁组70例,安慰剂组67例;主要结局为妊娠32-34周戒烟率,次要结局包括吸烟减少、出生体重、胎龄、早产及低出生体重发生率。
主要发现
- 生化验证的戒烟率:治疗6周后尼古丁组4%(3/70)vs 安慰剂组3%(2/67),p<0.99;妊娠32-34周尼古丁组10%(7/70)vs 安慰剂组18%(12/67),p=0.220。
- 每日吸烟支数两组均随时间下降(p<0.001),尼古丁组在戒烟日后2周(p=0.022)和6周(p=0.042)下降幅度大于安慰剂组,但妊娠32-34周时无显著差异(p=0.108)。
- 血清可替宁水平、出生体重、胎龄及一氧化碳下降幅度两组无差异。
- 早产发生率:尼古丁组4%(3/67)vs 安慰剂组15%(10/67),p=0.030。
- 低出生体重发生率:尼古丁组6%(4/67)vs 安慰剂组15%(10/67),p=0.035;校正早产后p=0.268。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Smoking during pregnancy is a serious public health problem in need of better treatments. Nicotine replacement treatment (NRT) (patch or gum) has not been shown in randomized placebo-controlled trials to be efficacious for smoking cessation during pregnancy. However, the nicotine inhaler may have advantages over other NRTs as it replicates some of the sensory effects of smoking. OBJECTIVE: The purpose of the study was examine the efficacy and safety of the nicotine inhaler for smoking cessation during pregnancy. We hypothesized that the nicotine inhaler compared to placebo would increase quit rates and reduce smoking during treatment and at the end of pregnancy, result in a higher birth weight and gestational age in the offspring, and reduce the incidence of preterm birth and low birth weight infants. STUDY DESIGN: We conducted a randomized, double-blind, placebo-controlled trial of the nicotine inhaler for smoking cessation during pregnancy. Pregnant women who smoked ≥5 cigarettes daily received behavioral counseling and random assignment to a 6-week treatment with nicotine or placebo inhaler, followed by a 6-week taper period. Throughout treatment, we assessed tobacco exposure biomarkers, cessation rates, and adverse events. We also obtained information on birth outcomes. The primary outcome was smoking cessation at 32-34 weeks gestation; secondary outcomes were smoking reduction, birth weight and gestational age, and the incidence of preterm birth or low birth weight infants. We compared treatment groups on these measures using t-tests, Fisher's exact tests, and multivariate linear and logistic regression. RESULTS: Participants in the placebo (n=67) and nicotine (n=70) groups were comparable on baseline characteristics, though women in the placebo group reported a higher motivation to quit (p=0.016). Biochemically-validated smoking cessation rates were similar with nicotine and placebo (after 6 weeks of treatment: 4% (3/70) vs. 3% (2/67), respectively, p< 0.99, and at 32-34 weeks gestation: 10% (7/70) vs. 18% (12/67), respectively, p=0.220). Cigarettes per day (CPD) decreased over time in both groups (p< 0.001), with the nicotine inhaler group having a greater decrease than the placebo group two (p=0.022) and six weeks after the quit date (p=0.042), but not at 32-34 weeks gestation (p=0.108). Serum cotinine levels, birth weight, gestational age and reductions in carbon monoxide did not differ by group. However, the incidence of preterm delivery was higher in the placebo than the nicotine group: 15% (10/67) vs. 4% (3/67), respectively, p=0.030). The incidence of delivering a low birth weight infant was also higher in the placebo than the nicotine group: 15% (10/67) vs. 6% (4/67), respectively, p=0.035, but not after adjusting for preterm delivery p=0.268. CONCLUSIONS: Although the nicotine inhaler group did not have a higher quit rate during pregnancy than the placebo group, the outcome of preterm delivery occurred less frequently in the nicotine group.
引用
- Oncken C, Dornelas EA, Kuo CL, et al. Randomized Trial of Nicotine Inhaler for Pregnant Smokers. Am J Obstet Gynecol MFM. 2019. PMID: 31380506. doi:10.1016/j.ajogmf.2019.03.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。